Company news

Amgen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis

May 4, 2021

Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study

April 27, 2021

Amgen Reports First Quarter 2021 Financial Results

April 26, 2021

Amgen Announces Webcast Of 2021 First Quarter Financial Results

April 21, 2021

Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing

April 18, 2021

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

April 15, 2021

Amgen to Acquire Rodeo Therapeutics Corporation

March 29, 2021

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

March 3, 2021

Amgen Announces 2021 Second Quarter Dividend

March 2, 2021

Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting

February 21, 2021

Amgen Reports Fourth Quarter And Full Year 2020 Financial Results

February 1, 2021

Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China

January 28, 2021

Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results

January 27, 2021

Amgen To Achieve Carbon Neutrality By 2027

January 10, 2021

Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency

December 21, 2020

Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral

December 16, 2020

Amgen Announces 10% Increase In 2021 First Quarter Dividend

December 15, 2020

Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation

December 7, 2020

Amgen Announces New Data Being Presented At ASH 2020

November 29, 2020

Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics

November 22, 2020

Amgen Presents First Clinical Data for AMG 757 at SITC 2020

November 8, 2020

Amgen Reports Third Quarter 2020 Financial Results

October 27, 2020

Amgen Announces Webcast Of 2020 Third Quarter Financial Results

October 26, 2020

Amgen Announces 2020 Fourth Quarter Dividend

October 20, 2020

Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure

October 7, 2020

Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer

October 4, 2020

Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine

October 2, 2020

Amgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020

September 15, 2020

Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020

August 28, 2020

FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens

August 19, 2020

Amgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes

August 12, 2020

Amgen Commences Exchange Offers For Certain Series Of Outstanding Senior Notes From Exchange Eligible Holders

July 29, 2020

Amgen Reports Second Quarter 2020 Financial Results

July 27, 2020

Amgen Announces Webcast Of 2020 Second Quarter Financial Results

July 22, 2020

Amgen Foundation Awards Khan Academy An Additional $3 Million To Support Science Learning And Educational Equity Amid COVID-19

July 20, 2020

Amgen Announces Additional Investment In BeiGene

July 11, 2020

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

January 12, 2020

Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration

December 18, 2019

European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

December 10, 2019

Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub

December 8, 2019

FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)

December 5, 2019

Amgen Announces Data Being Presented At ASH 2019

December 1, 2019

Amgen Completes Acquisition Of Otezla® (apremilast)

November 20, 2019

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

November 15, 2019

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

November 14, 2019

Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China

October 30, 2019

Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation

October 22, 2019

Amgen Announces 2019 Fourth Quarter Dividend

October 21, 2019

EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

October 16, 2019

Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

October 8, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.